KIT and acute myeloid leukemia: The present study demonstrated a higher frequency of CD7 than other investigations, ranging from 8.8% to 33%.(16,27) CD7 expression in myeloblasts has been associated with failure to achieve complete remission and decreased survival.(28,29) It is believed that CD7 is expressed in early stages of hematopoietic ontogeny and has been associated with expression of precursor antigens.(28,30) Corroborating this statement, we found the expression of markers linked to cellular immaturity, such as HLA-DR in 91.4%, CD117 in 97.8%, and CD34 in 87.6% of CD7 positive AML cases.